Ruxolitinib for Steroid-refractory GVHD
Treatment of Steroid-refractory Acute and Chronic Graft-versus-host Disease With Inhibitor of Janus Kinases
Sponsor: Ministry of Health, Russian Federation
A PHASE2 clinical study on Graft Vs Host Disease, this trial is completed. The trial is conducted by Ministry of Health, Russian Federation and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
May 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Oct 2018 — May 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE2
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ministry of Health, Russian Federation
- St. Petersburg State Pavlov Medical University
For direct contact, visit the study record on ClinicalTrials.gov .